Skip to content
sellWeak cluster of 210b5-1 plan

Scott Bizily sold $22k of FDMT

Chief Legal Officer at 4D Molecular Therapeutics, Inc.. 1,635 shares at an average of $13.65, traded Sep 16, 2026, filed Sep 22, 2026.

Warning score
0
Value
$22k
1,635 shares
Holdings after
8,617
-16% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $22k at market
    0
  • Share of holdings sold
    Sold 16% of holdings
    +5
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

FDMTOct 9, 2026 · close 13.33
Since filing Sep 22, 2026: -16.1%SPY +0.7% · excess -16.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-26-398204, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Sep 16, 2026MOption exercise
Common Stock10b5-1
+1,635$4.14$6,76910,25220 d ago
Sep 16, 2026SOpen-market sale
Common Stock10b5-1
-1,635$13.65$22k8,61720 d ago
Sep 16, 2026MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-1,635$0.00$058,06620 d ago

Related signals

Other insiders at 4D Molecular Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
17Weak
FDMTsell10b5-1
4D Molecular Therapeutics, Inc.
David Kirn
See Remarks
$754k
58,333 shares
-8%
25Weak
FDMTsell 210b5-1
4D Molecular Therapeutics, Inc.
David Kirn
See Remarks
$811k
58,333 shares
-7%
0Weak
FDMTsell 210b5-1
4D Molecular Therapeutics, Inc.
Scott Bizily
Chief Legal Officer
$8,176
584 shares
-6%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Scott Bizily sold $22k of FDMT | InsiderTell